MBK Partners keen to operate on China’s AsiaPharm
Asia bucked the global trend this week with confirmation of the leveraged buyout of Chinese drug maker AsiaPharm Group by MBK Partners and existing management. Asia’s first new LBO of the year comes at a time when the leveraged market in the rest of the world is still swimming in a flood of hung deals. Find out which banks are braving the market to finance the S$357.4m takeover in your next issue of EuroWeek.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts